Checkpoint inhibition in CNS lymphoma
- PMID: 28596436
- DOI: 10.1182/blood-2017-04-777797
Checkpoint inhibition in CNS lymphoma
Conflict of interest statement
Conflict-of-interest disclore: B.C. received research funding from Bristol-Myers Squibb, Merck, Genentech, Celgene, Seattle Genetics, Immunomedics, Acerta, Janssen, and Pharmacyclics and is on the Arzerra data safety monitoring board.
Comment on
-
PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.Blood. 2017 Jun 8;129(23):3071-3073. doi: 10.1182/blood-2017-01-764209. Epub 2017 Mar 29. Blood. 2017. PMID: 28356247 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical